We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-8.42%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$110M
AUM Growth
-$70.1M
Cap. Flow
-$48.5M
Cap. Flow %
-43.92%
Top 10 Hldgs %
98.11%
Holding
13
New
–
Increased
3
Reduced
7
Closed
1

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$3.75M
2
KYMR icon
Kymera Therapeutics
KYMR
+$2.63M
3
ARWR icon
Arrowhead Research
ARWR
+$1.53M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$8.37M
2
ARGX icon
argenx
ARGX
+$6.16M
3
GMAB icon
Genmab
GMAB
+$4.67M
4
BPMC
Blueprint Medicines
BPMC
+$3.74M
5
ARVN icon
Arvinas
ARVN
+$3.31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARWR icon
1
Arrowhead Research
ARWR
$12.4B
$24.4M 22.12%
908,474
+50,000
+6% +$1.53M
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$19M 17.25%
379,090
-69,897
-16% -$3.74M
RGNX icon
3
Regenxbio
RGNX
$708M
$13.9M 12.64%
847,424
-22,690
-3% -$411K
SLN
4
Silence Therapeutics
SLN
$564M
$12.9M 11.68%
1,312,233
– –
KYMR icon
5
Kymera Therapeutics
KYMR
$8.94B
$10.9M 9.85%
782,219
+130,894
+20% +$2.63M
MRUS
6
DELISTED
Merus
MRUS
$10.1M 9.19%
430,109
-345,000
-45% -$8.37M
ARVN icon
7
Arvinas
ARVN
$572M
$9.61M 8.71%
489,153
-134,788
-22% -$3.31M
CCCC icon
8
C4 Therapeutics
CCCC
$412M
$3.7M 3.35%
1,990,334
+1,229,677
+162% +$3.75M
GMAB icon
9
Genmab
GMAB
$19.5B
$1.84M 1.67%
52,148
-122,500
-70% -$4.67M
ARGX icon
10
argenx
ARGX
$54.1B
$1.83M 1.66%
3,715
-12,600
-77% -$6.16M
OLMA icon
11
Olema Pharmaceuticals
OLMA
$1.05B
$1.1M 0.99%
88,875
-161,125
-64% -$1.64M
PVLA
12
Palvella Therapeutics
PVLA
$2.27B
$984K 0.89%
41,290
– –
IWM icon
13
PUT
iShares Russell 2000 ETF
IWM
$81.9B
– –
-150,000
Closed -$28.1M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, Aquilo Capital Management held 13 positions worth $110M, down 39% from $180M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Aquilo Capital Management withdrew a net $48.5M in Q3 2023, closing 1 position and reducing 7 holdings. Its largest reduction was Merus, cutting an estimated $8.37M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 84% a quarter earlier.

Against the trend, Aquilo Capital Management added an estimated $3.75M to C4 Therapeutics.

  • Aquilo Capital Management added most to C4 Therapeutics in Q3 2023, an estimated $3.75M increase.
  • Aquilo Capital Management's biggest Q3 2023 reduction was Merus, cutting an estimated $8.37M.
  • Aquilo Capital Management's ten largest holdings make up 98% of its $110M portfolio in Q3 2023.
  • Aquilo Capital Management opened 0 new positions and closed 1 in Q3 2023.
  • Aquilo Capital Management's portfolio value fell 39% quarter-over-quarter to $110M.

Based on Aquilo Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.